DBV Technologies
Develops epicutaneous immunotherapy (EPIT) patch technology for food allergies.
DBV | PA
Overview
Corporate Details
- ISIN(s):
- FR0010417345 (+3 more)
- LEI:
- 969500PVBQFWQKVDMD80
- Country:
- France
- Address:
- 107 AVENUE DE LA REPUBLIQUE, 92320 CHATILLON
- Sector:
- Manufacturing
Description
DBV Technologies is a clinical-stage biopharmaceutical company developing treatments for food allergies and other immunological diseases. The company's core technology is Viaskin®, a proprietary investigational platform based on epicutaneous immunotherapy (EPIT). This non-invasive patch technology is designed to re-educate the immune system by delivering minimal amounts of antigens through intact skin. DBV's lead product candidate, Viaskin Peanut (DBV712), is in late-stage clinical development for the treatment of peanut allergies in pediatric patients. The development pipeline also includes Viaskin Milk (DBV135) for milk allergies, with the platform holding potential for applications beyond food allergies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-13 17:51 |
Franchissement de seuils
|
French | 271.9 KB | ||
| 2025-11-12 05:50 |
DBV Technologies annonce la dernière visite du dernier patient dans l'essai cli…
|
French | 219.7 KB | ||
| 2025-11-12 05:50 |
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clin…
|
English | 220.0 KB | ||
| 2025-10-30 21:30 |
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Con…
|
French | 197.8 KB | ||
| 2025-10-30 21:30 |
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Direct…
|
English | 194.0 KB | ||
| 2025-10-28 21:25 |
DBV Technologies Reports Third Quarter 2025 Financial Results
|
English | 272.3 KB | ||
| 2025-10-28 21:25 |
DBV Technologies publie ses résultats financiers du troisième trimestre 2025
|
French | 274.7 KB | ||
| 2025-10-14 15:44 |
Franchissement de seuils
|
French | 266.6 KB | ||
| 2025-06-20 12:46 |
Franchissement de seuils
|
French | 124.2 KB | ||
| 2025-06-17 16:58 |
Franchissement de seuils
|
French | 107.2 KB | ||
| 2025-06-12 22:05 |
DBV Technologies to Participate in Upcoming EAACI Congress 2025
|
English | 275.8 KB | ||
| 2025-06-12 22:05 |
DBV Technologies participera au prochain congrès EAACI 2025
|
French | 269.7 KB | ||
| 2025-06-11 22:30 |
DBV Technologies annonce les résultats de son Assemblée Générale Mixte 2025
|
French | 179.9 KB | ||
| 2025-06-11 22:30 |
DBV Technologies Announces the Voting Results of its 2025 Combined General Meet…
|
English | 179.7 KB | ||
| 2025-06-04 22:32 |
Information Regarding the Total Number of Voting Rights and Total Number of Sha…
|
English | 169.6 KB |
Automate Your Workflow. Get a real-time feed of all DBV Technologies filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for DBV Technologies
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for DBV Technologies via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-09 | N/A | Other | Other | 2,483,161 | 7,449,483.00 EUR |
Peer Companies
